

## Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines

### CURATIVE BIOTECHNOLOGY, INC.

561-907-8990

curativebiotech.com

ir@curativebiotech.com

SIC – 8731/8733

#### Quarterly Report

**For the Period Ending: March 31, 2021**

(the "Reporting Period")

As of May 24, 2021, the number of shares outstanding of our Common Stock was:

524,341,194

As of December 31, 2020, the number of shares outstanding of our Common Stock was:

333,000,327

As of December 31, 2019, the number of shares outstanding of our Common Stock was:

322,800,327

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934):

Yes:  No:

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes:  No:

Indicate by check mark whether a Change in Control<sup>1</sup> of the company has occurred over this reporting period:

Yes:  No:

---

<sup>1</sup> "Change in Control" shall mean any events resulting in:

(i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;

(ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;

(iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or

(iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

**1) Name and address(es) of the issuer and its predecessors (if any)**

In answering this item, provide the current name of the issuer any names used by predecessor entities, along with the dates of the name changes.

Curative Biotechnology, Inc., herein referred to as "CUBT" or the "Company."

The company was formerly known as: Connectyx Technologies Holdings Group, Inc., until April 2021, Storage Innovation Technologies, Inc. until 10-07; National Boston Medical, Inc. until 5-04; Fragrance Express, Inc. until 10-98; Growth Industries, Inc. until 7-98

The state of incorporation or registration of the issuer and of each of its predecessors (if any) during the past five years; Please also include the issuer's current standing in its state of incorporation (e.g. active, default, inactive):

The Company was originally incorporated on June 29, 1995, in the State of Nevada; the Company, as of October 31, 2007, was reincorporated in the State of Florida and is active in Florida.

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors since inception:

N/A

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

None

The address of the issuer's principal executive office:

1825 NW Corporate Blvd., Suite 110  
Boca Raton, FL 33431

The address(es) of the issuer's principal place of business:

*Check box if principal executive office and principal place of business are the same address:*

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

Yes:  No:

If this issuer or any of its predecessors have been the subject of such proceedings, please provide additional details in the space below:

N/A

## 2) Security Information

Trading symbol: CUBT  
Exact title and class of securities outstanding: Common Stock  
CUSIP: 23128N108  
Par or stated value: \$0.0001

Total shares authorized: 1,100,000,000 as of date: 05/24/2021  
Total shares outstanding: 524,341,194 as of date: 05/24/2021  
Number of shares in the Public Float<sup>2</sup>: 238,454,480 as of date: 05/24/2021  
Total number of shareholders of record: 198 as of date: 05/24/2021

*All additional class(es) of publicly traded securities (if any): N/A*

Trading symbol: \_\_\_\_\_  
Exact title and class of securities outstanding: \_\_\_\_\_  
CUSIP: \_\_\_\_\_  
Par or stated value: \_\_\_\_\_  
Total shares authorized: \_\_\_\_\_ as of date: \_\_\_\_\_  
Total shares outstanding: \_\_\_\_\_ as of date: \_\_\_\_\_

### Transfer Agent

Name: Issuer Direct Corporation  
Address: One Glenwood Ave, Suite 1001  
Address 2: Raleigh, NC 27603  
Phone: +1 (919) 481-4000  
Email: info@issuereirect.com

Is the Transfer Agent registered under the Exchange Act?<sup>3</sup> Yes:  No:

## 3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any direct changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period**.

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

### A. Changes to the Number of Outstanding Shares

Check this box to indicate there were no changes to the number of outstanding shares within the past two completed fiscal years and any subsequent periods:

---

<sup>2</sup> "Public Float" shall mean the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding (a "control person"), or any affiliates thereof, or any immediate family members of officers, directors and control persons.

<sup>3</sup> To be included in the Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

Shares Outstanding as of Second Most Recent Fiscal Year End:

Opening Balance

Date 12/31/18

Common: 322,800,327

Series A Preferred:  
34,109,750

Series B Preferred:  
293,000

\*Right-click the rows below and select "Insert" to add rows as needed.

Date of Transaction	Transaction type (e.g. new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to (entities must have individual with voting / investment control disclosed).	Reason for share issuance (e.g. for cash or debt conversion) -OR- Nature of Services Provided	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.
<u>3/5/20</u>	<u>New Issuance</u>	<u>1,500,000</u>	<u>Common</u>	<u>.01</u>	<u>No</u>	David Alfred Karram and Sarah Margaret Karram	<u>Web Design and Hosting</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>4/28/20</u>	<u>New Issuance</u>	<u>500,000</u>	<u>Common</u>	<u>.0016</u>	<u>No</u>	Pamela Bisikirski and John Bisikirski	<u>Marketing</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>5/8/20</u>	<u>New Issuance</u>	<u>250,000</u>	<u>Common</u>	<u>.01</u>	<u>No</u>	Ronald W. Bordens, Ph.D	<u>Scientific Advisory Board</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>5/8/20</u>	<u>New Issuance</u>	<u>250,000</u>	<u>Common</u>	<u>.01</u>	<u>No</u>	Michael J. Grace, Ph.D	<u>Scientific Advisory Board</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>5/18/20</u>	<u>New Issuance</u>	<u>250,000</u>	<u>Common</u>	<u>.01</u>	<u>No</u>	I Richard Garr, JD	<u>Scientific Advisory Board</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>10/8/20</u>	<u>New Issuance</u>	<u>7,000,000</u>	<u>Common</u>	<u>.013</u>	<u>No</u>	Mid Atlantic BioTherapeutics / David Horn, MD	<u>License Execution</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>11/8/20</u>	<u>New Issuance</u>	<u>100,000</u>	<u>Common</u>	<u>.03</u>	<u>No</u>	Michael K. Fish	<u>Board Fee</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>11/11/20</u>	<u>New Issuance</u>	<u>50,000,000</u>	<u>Series A Preferred</u>	<u>\$.0001</u>	<u>N/A</u>	Dr. Barry A. Ginsberg	<u>Services</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>11/11/20</u>	<u>New Issuance</u>	<u>50,000,000</u>	<u>Series A Preferred</u>	<u>\$.0001</u>	<u>N/A</u>	Paul M. Michaels	<u>Services</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>11/11/20</u>	<u>New Issuance</u>	<u>6,000,000</u>	<u>Series C Preferred</u>	<u>\$.0001</u>	<u>N/A</u>	Ronald W. Bordens, Ph.D	<u>Services</u>	<u>Restricted</u>	<u>4(a)(2)</u>

<u>11/11/20</u>	<u>New Issuance</u>	6,000,000	<u>Series C Preferred</u>	\$.0001	<u>N/A</u>	Michael J. Grace, Ph.D	<u>Services</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>11/11/20</u>	<u>New Issuance</u>	6,000,000	<u>Series C Preferred</u>	\$.0001	<u>N/A</u>	I Richard Garr, JD	<u>Services</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>11/11/20</u>	<u>New Issuance</u>	6,000,000	<u>Series C Preferred</u>	\$.0001	<u>N/A</u>	Dr. Barry A . Ginsberg	<u>Services</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>11/11/20</u>	<u>New Issuance</u>	6,000,000	<u>Series C Preferred</u>	\$.0001	<u>N/A</u>	Paul M. Michaels	<u>Services</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>12/3/20</u>	<u>New Issuance</u>	<u>250,000</u>	<u>Common</u>	<u>.03</u>	<u>No</u>	Ivel Realty Associates Corp / Marc Lewis	<u>Consulting</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>12/9/20</u>	<u>New Issuance</u>	<u>40,000</u>	<u>Common</u>	<u>.03</u>	<u>No</u>	Zabrina Langer	<u>Consulting</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>12/9/20</u>	<u>New Issuance</u>	<u>30,000</u>	<u>Common</u>	<u>.03</u>	<u>No</u>	Theodore Langer	<u>Consulting</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>12/9/20</u>	<u>New Issuance</u>	<u>30,000</u>	<u>Common</u>	<u>.03</u>	<u>No</u>	Samuel Langer	<u>Consulting</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>01/29/21</u>	<u>New Issuance</u>	<u>27,066,666</u>	<u>Common</u>	<u>.0075</u>	<u>No</u>	Green Life, Inc.  (Barry A. Ginsberg)	<u>Conversion of Series B Preferred</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>1/29/201</u>	<u>Cancelation</u>	<u>203,000</u>	<u>Series B Preferred</u>	<u>N/A</u>	<u>N/A</u>	Green Life, Inc.  (Barry A. Ginsberg)			
<u>02/17/21</u>	<u>New Issuance</u>	<u>5,000,000</u>	<u>Common</u>	<u>.05</u>	<u>No</u>	Rochelle Langer	<u>Warrant Exercise</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>02/17/21</u>	<u>New Issuance</u>	<u>500,000</u>	<u>Common</u>	<u>.05</u>	<u>No</u>	Rochelle Langer	<u>Warrant Exercise</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>02/17/21</u>	<u>New Issuance</u>	<u>500,000</u>	<u>Common</u>	<u>.05</u>	<u>No</u>	Rochelle Langer	<u>Warrant Exercise</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>02/17/21</u>	<u>New Issuance</u>	<u>40,000</u>	<u>Common</u>	<u>.044</u>	<u>No</u>	Zabrina Langer	<u>Consulting</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>02/17/21</u>	<u>New Issuance</u>	<u>500,000</u>	<u>Common</u>	<u>.05</u>	<u>No</u>	Theodore Langer	<u>Warrant Exercise</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>02/17/21</u>	<u>New Issuance</u>	<u>30,000</u>	<u>Common</u>	<u>.044</u>	<u>No</u>	Theodore Langer	<u>Consulting</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>02/17/21</u>	<u>New Issuance</u>	<u>200,000</u>	<u>Common</u>	<u>.05</u>	<u>No</u>	Samuel Langer	<u>Warrant Exercise</u>	<u>Restricted</u>	<u>3(a)(9)</u>

<u>02/17/21</u>	<u>New Issuance</u>	<u>30,000</u>	<u>Common</u>	<u>.044</u>	<u>No</u>	Samuel Langer	<u>Consulting</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>02/17/21</u>	<u>New Issuance</u>	<u>300,000</u>	<u>Common</u>	<u>.05</u>	<u>No</u>	Aaron Charapp	<u>Warrant Exercise</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>02/17/21</u>	<u>New Issuance</u>	<u>250,000</u>	<u>Common</u>	<u>.05</u>	<u>No</u>	Ivel Realty Associates (Marc Lewis)	<u>Warrant Exercise</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/12/21</u>	<u>New Issuance</u>	<u>6,500,000</u>	<u>Common</u>	<u>.05</u>	<u>No</u>	Rochelle Langer	<u>Warrant</u>		
<u>03/12/21</u>	<u>New Issuance</u>	<u>1,000,000</u>	<u>Common</u>	<u>.05</u>	<u>No</u>	Peter and Gail Capuano	<u>Warrant Exercise</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/12/21</u>	<u>New Issuance</u>	<u>250,000</u>	<u>Common</u>	<u>.05</u>	<u>No</u>	Charles K McHenry	<u>Warrant Exercise</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/12/21</u>	<u>New Issuance</u>	<u>250,000</u>	<u>Common</u>	<u>.05</u>	<u>No</u>	Josh York	<u>Warrant Exercise</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/12/21</u>	<u>New Issuance</u>	<u>250,000</u>	<u>Common</u>	<u>.05</u>	<u>No</u>	Joseph Gantz	<u>Warrant Exercise</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/12/21</u>	<u>New Issuance</u>	<u>100,000</u>	<u>Common</u>	<u>.05</u>	<u>No</u>	John Acito	<u>Warrant Exercise</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/12/21</u>	<u>New Issuance</u>	<u>300,000</u>	<u>Common</u>	<u>.05</u>	<u>No</u>	Timothy Sellew	<u>Warrant Exercise</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/12/21</u>	<u>New Issuance</u>	<u>100,000</u>	<u>Common</u>	<u>.05</u>	<u>No</u>	SJ Stile Associates, Ltd (Milton Heid)	<u>Warrant Exercise</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/12/21</u>	<u>New Issuance</u>	<u>1,041,667</u>	<u>Common</u>	<u>.06</u>	<u>No</u>	Rochelle Langer	<u>Note Conversion</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/12/21</u>	<u>New Issuance</u>	<u>1,041,667</u>	<u>Common</u>	<u>.06</u>	<u>No</u>	Rochelle Langer	<u>Note Conversion</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/12/21</u>	<u>New Issuance</u>	<u>1,041,667</u>	<u>Common</u>	<u>.06</u>	<u>No</u>	Theodore Langer	<u>Note Conversion</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/12/21</u>	<u>New Issuance</u>	<u>2,083,333</u>	<u>Common</u>	<u>.06</u>	<u>No</u>	Peter and Gail Capuano	<u>Note Conversion</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/12/21</u>	<u>New Issuance</u>	<u>520,833</u>	<u>Common</u>	<u>.06</u>	<u>No</u>	GG Capital, LLC (Joseph Gantz)	<u>Note Conversion</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/12/21</u>	<u>New Issuance</u>	<u>416,667</u>	<u>Common</u>	<u>.06</u>	<u>No</u>	Samuel Langer	<u>Note Conversion</u>	<u>Restricted</u>	<u>3(a)(9)</u>

<u>03/12/21</u>	<u>New Issuance</u>	<u>208.333</u>	<u>Common</u>	<u>.06</u>	<u>No</u>	John Acito	<u>Note Conversion</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/12/21</u>	<u>New Issuance</u>	<u>625.000</u>	<u>Common</u>	<u>.06</u>	<u>No</u>	Aaron Charapp	<u>Note Conversion</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/12/21</u>	<u>New Issuance</u>	<u>625.000</u>	<u>Common</u>	<u>.06</u>	<u>No</u>	Timothy Sellew	<u>Note Conversion</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/12/21</u>	<u>New Issuance</u>	<u>208.333</u>	<u>Common</u>	<u>.06</u>	<u>No</u>	Stile Associates Ltd  (Milton Heid)	<u>Note Conversion</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/12/21</u>	<u>New Issuance</u>	<u>520.833</u>	<u>Common</u>	<u>.06</u>	<u>No</u>	Josh York	<u>Note Conversion</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/12/21</u>	<u>New Issuance</u>	<u>520.833</u>	<u>Common</u>	<u>.06</u>	<u>No</u>	Charles McHenry	<u>Note Conversion</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/17/21</u>	<u>New Issuance</u>	<u>400.000</u>	<u>Common</u>	<u>.03</u>	<u>No</u>	Max McKenna	<u>Website Development</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/25/21</u>	<u>New Issuance</u>	<u>1,000.000</u>	<u>Common</u>	<u>.05</u>	<u>No</u>	Jose Bardelas	<u>Warrant Exercise</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/26/21</u>	<u>New Issuance</u>	<u>2,083.333</u>	<u>Common</u>	<u>.06</u>	<u>No</u>	Jose Bardelas	<u>Note Conversion</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/30/21</u>	<u>New Issuance</u>	<u>2,921.844</u>	<u>Common</u>	<u>N/A</u>	<u>N/A</u>	Jeff Frankel	<u>Conversion of Series A Preferred</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/30/21</u>	<u>New Issuance</u>	<u>3,565.437</u>	<u>Common</u>	<u>N/A</u>	<u>N/A</u>	William Carlson	<u>Conversion of Series A Preferred</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/30/21</u>	<u>New Issuance</u>	<u>50,643.813</u>	<u>Common</u>	<u>N/A</u>	<u>N/A</u>	Barry Ginsberg	<u>Conversion of Series A Preferred</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/30/21</u>	<u>New Issuance</u>	<u>50,643.813</u>	<u>Common</u>	<u>N/A</u>	<u>N/A</u>	Paul Michaels	<u>Conversion of Series A Preferred</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/30/21</u>	<u>New Issuance</u>	<u>21,931.765</u>	<u>Common</u>	<u>N/A</u>	<u>N/A</u>	Sunmed Advisors, LLC  (Barry A. Ginsberg)  (Paul Michaels)	<u>Conversion of Series A Preferred</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/30/21</u>	<u>New Issuance</u>	<u>3,646.396</u>	<u>Common</u>	<u>N/A</u>	<u>N/A</u>	Al Forcella	<u>Conversion of Series A Preferred</u>	<u>Restricted</u>	<u>3(a)(9)</u>

<u>03/30/21</u>	<u>New Issuance</u>	<u>645,767</u>	<u>Common</u>	<u>N/A</u>	<u>N/A</u>	Amanda Schuman	<u>Conversion of Series A Preferred</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/30/21</u>	<u>New Issuance</u>	<u>293,734</u>	<u>Common</u>	<u>N/A</u>	<u>N/A</u>	David Evrard	<u>Conversion of Series A Preferred</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/30/21</u>	<u>New Issuance</u>	<u>391,983</u>	<u>Common</u>	<u>N/A</u>	<u>N/A</u>	Gary Kabinoff	<u>Conversion of Series A Preferred</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/30/21</u>	<u>New Issuance</u>	<u>645,709</u>	<u>Common</u>	<u>N/A</u>	<u>N/A</u>	Steven Landau	<u>Conversion of Series A Preferred</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/30/21</u>	<u>New Issuance</u>	<u>253,219</u>	<u>Common</u>	<u>N/A</u>	<u>N/A</u>	MDM Management Corp II  (Michael McMeans)	<u>Conversion of Series A Preferred</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/30/21</u>	<u>New Issuance</u>	<u>253,219</u>	<u>Common</u>	<u>N/A</u>	<u>N/A</u>	Andrew L Phinney	<u>Conversion of Series A Preferred</u>	<u>Restricted</u>	<u>3(a)(9)</u>
<u>03/30/21</u>	<u>Cancellation</u>	<u>134,109,750</u>	<u>Series A Preferred</u>	<u>N/A</u>	<u>N/A</u>	All Series A Holders	<u>Conversion to Common</u>	<u>N/A</u>	<u>N/A</u>
<u>05/12/2021</u>	<u>New Issuance</u>	<u>250,000</u>	<u>Common</u>	<u>.02</u>	<u>No</u>	Dimiter Dimitrov	<u>Scientific Advisory Board fee</u>		<u>4(a)(2)</u>

Shares Outstanding on Date of This Report:

<u>Ending</u>	<u>Balance</u>
<u>Ending Balance:</u>	
Date <u>05/24/21</u>	Common: <u>524,341,194</u>
	Series A Preferred: 0.00
	Series B Preferred: 90,000
	Series C Preferred: 30,000,000

**Example:** A company with a fiscal year end of December 31<sup>st</sup>, in addressing this item for its quarter ended September 30, 2020, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2018 through September 30, 2020 pursuant to the tabular format above.

Use the space below to provide any additional details, including footnotes to the table above:

\_\_\_\_\_



## B. Debt Securities, Including Promissory and Convertible Notes

Use the chart and additional space below to list and describe all outstanding promissory notes, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities.

Check this box if there are no outstanding promissory, convertible notes or debt arrangements:

Date of Note Issuance	Outstanding Balance (\$)	Principal Amount at Issuance (\$)	Interest Accrued (\$)	Maturity Date	Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares)	Name of Noteholder (entities must have individual with voting / investment control disclosed).	Reason for Issuance (e.g. Loan, Services, etc.)
_____	_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____	_____

Use the space below to provide any additional details, including footnotes to the table above:

During the 4th quarter the Company entered into 11 notes payable for a total amount of cash received of \$385,000. The notes are identical and carry a maturity of six months from inception and a 25% fixed interest payment. The maturity is extendable at the Company's option for up to three months with a 3% per month extension fee. The notes also carry 10 warrants for each \$1 loaned. These notes are collateralized by Preferred C shares representing 9.24% of the issued and outstanding common stock shares. Two officers holding these Preferred C shares are pledged have pledged them as this collateral.

## 4) Financial Statements

A. The following financial statements were prepared in accordance with:

- U.S. GAAP  
 IFRS

B. The financial statements for this reporting period were prepared by (name of individual)<sup>4</sup>:

Name: **Michael K. Fish**  
Title: **Certified Public Accountant**  
Relationship to Issuer: **Director**

Provide the financial statements described below for the most recent fiscal year or quarter. For the initial disclosure statement (qualifying for Pink Current Information for the first time) please provide reports for the two previous fiscal years and any subsequent interim periods.

- C. Balance sheet;  
D. Statement of income;  
E. Statement of cash flows;

<sup>4</sup> The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS by persons with sufficient financial skills.

- F. Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- G. Financial notes; and
- H. Audit letter, if audited

You may either (i) attach/append the financial statements to this disclosure statement or (ii) file the financial statements through OTCIQ as a separate report using the appropriate report name for the applicable period end. ("Annual Report," "Quarterly Report" or "Interim Report").

If you choose to publish the financial statements in a separate report as described above, you must state in the accompanying disclosure statement that such financial statements are incorporated by reference. You may reference the document(s) containing the required financial statements by indicating the document name, period end date, and the date that it was posted to OTCIQ in the field below. Financial Statements must be compiled in one document.

**The unaudited financial statements for the period ended 03/31/2021 are attached hereto**

Financial statement information is considered current until the due date for the subsequent report (as set forth in the qualifications section above). To remain qualified for Current Information, a company must post its Annual Report within 90 days from its fiscal year-end date and Quarterly Reports within 45 days of each fiscal quarter-end date.

## 5) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. In answering this item, please include the following:

- A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

Curative Biotechnologies, Inc. (CUBT) is a development stage biotechnology innovator focusing on novel treatments for rare diseases and therapies with accelerated development paths. At the heart of our process is a product development engine that rests on our unique S.O.A.R. filter (Science, Opportunity, Acceleration, Rare Disease). Our first-generation portfolio under development includes a novel monoclonal antibody drug conjugate to treat newly diagnosed glioblastoma, a novel immunotherapy to treat late-stage rabies, and a reformulated version of the drug Metformin as a topical administration to treat degenerative eye diseases. At Curative Biotech we envision a world where all patients have a therapeutic option.

- B. Please list any subsidiaries, parents, or affiliated companies.

N/A

- C. Describe the issuers' principal products or services.

The Company is focused on developing therapies with potentially accelerated development paths as a result of either the disease, the nature of the therapeutic itself, or the stage of clinical development. The Company operates on an outsource model, where it's core management group oversees a network of subject matter experts, clinical advisors, manufacturing vendors and regulatory consultants.

## 6) Issuer's Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

The Company utilizes virtual office space at a cost of \$99 per month.

## 7) Company Insiders (Officers, Directors, and Control Persons)

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial shareholders.

Using the tabular format below, please provide information, as of the period end date of this report, regarding any person or entity owning 5% of more of any class of the issuer's securities, as well as any officer, and any director of the company, or any person that performs a similar function, regardless of the number of shares they own. **If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity in the note section.**

Name of Officer/Director or Control Person	Affiliation with Company (e.g. Officer Title /Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Note
Paul M. Michaels	Officer and Director	Boca Raton, FL	<u>47,643,813</u>	Common	9.11%	
			6,000,000	Series C Preferred	20%	
Dr. Barry A. Ginsberg	Officer and Director	Boca Raton, FL	<u>60,710,479</u>	Common	11.61%	
			6,000,000	Series C Preferred	20%	
Michael K. Fish	Director	Miami, FL	200,000	Common	<1%	
I Richard Garr, JD	Officer	Delray Beach, FL	20,250,000	Common	<u>3.87%</u>	
			6,000,000	Series C Preferred	20%	
Ronald W. Bordens, Ph.D	Officer	Boynton Beach, FL	250,000	Common	<u>&lt;1%</u>	
			6,000,000	Series C Preferred	20%	
Michael J.	Advisor	Hamilton, NJ	250,000	Common	<u>&lt;1%</u>	

Grace, Ph.D			6,000,000	Series C Preferred	20%	
-------------	--	--	-----------	--------------------	-----	--

### 8) Legal/Disciplinary History

A. Please identify whether any of the persons or entities listed above have, in the past 10 years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

N/A

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

N/A

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

N/A

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

N/A

B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

None

### 9) Third Party Providers

Please provide the name, address, telephone number and email address of each of the following outside providers:

#### Securities Counsel

Name: Jonathan Leinwand  
Firm: Jonathan D. Leinwand, P.A.  
Address 1: 18305 Biscayne Blvd., Suite 200  
Address 2: Aventura, FL 33180  
Phone: 954-903-7856  
Email: jonathan@jdlpa.com

#### Accountant or Auditor

Name: Michael K. Fish

Firm: Michael K. Fish, CPA PA  
Address 1: 7700 N Kendall Dr. #405,  
Address 2: Miami, FL 33156  
Phone: 305-279-8484

Investor Relations

N/A

Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s) or consultant(s) or provided assistance or services to the issuer during the reporting period.

N/A

## 10) Issuer Certification

*Principal Executive Officer:*

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, I Richard Garr, certify that:

1. I have reviewed this quarterly disclosure statement of Curative Biotechnology Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

May 24, 2021 [Date]

/s/ I Richard Garr [CEO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

*Principal Financial Officer:*

I, I Richard Garr, certify that:

1. I have reviewed this quarterly disclosure statement of Curative Biotechnology Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

May 24, 2021 [Date]

/s/ I Richard Garr [CFO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

## INDEX TO UNAUDITED FINANCIAL STATEMENTS

Balance Sheets .....	F-2
Statements of Operations .....	F-3
Statement of Stockholders' Equity .....	F-4
Statements of Cash Flows .....	F-5
Notes to Financial Statements .....	F-6

**Curative Biotechnology, Inc**  
**(f/k/a Connectyx Technologies Holdings Group, Inc.)**  
**Balance Sheets**  
(Unaudited)

	<u>March 31,</u> <u>2021</u>	<u>December</u> <u>31, 2020</u>
<b>ASSETS</b>		
<b>CURRENT ASSETS</b>		
Cash	\$ 564,546	\$ 160,607
Other short term receivables	<u>-</u>	<u>70,000</u>
Total current assets	<u>564,546</u>	<u>230,607</u>
<b>FIXED ASSETS</b>		
Property and equipment	81,515	81,515
Accumulated depreciation	<u>(79,312)</u>	<u>(79,177)</u>
Total Fixed Assets	<u>2,203</u>	<u>2,338</u>
<b>OTHER ASSETS</b>		
Intangible assets, net of amortization	<u>133,175</u>	<u>140,300</u>
Total other assets	<u>133,175</u>	<u>140,300</u>
Total Assets	<u>\$ 699,924</u>	<u>\$ 373,245</u>
<b>LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)</b>		
<b>CURRENT LIABILITIES</b>		
Accounts payable and accrued liabilities	\$ 31,434	\$ 97,831
Short term note payable - related parties, net of discounts	43,939	25,415
Short term note payable - third parties, net of discounts	<u>-</u>	<u>405,647</u>
Total current liabilities	<u>75,373</u>	<u>528,893</u>
Total Liabilities	<u>75,373</u>	<u>528,893</u>
Commitments and Contingencies	-	-
<b>STOCKHOLDERS' EQUITY (DEFICIT)</b>		
Preferred stock, \$0.0001 par value, authorized 205,000,000 shares, zero and 134,109,750 Series A; 90,000 and 293,000 Series B and 30,000,000 and 30,000,000 Series C shares issued and outstanding	3,009	16,440
Common stock, \$0.0001 par value, authorized 1,100,000,000 shares; 524,341,194 and 333,000,327 shares issued and outstanding	52,434	33,300
Additional paid-in capital	5,122,062	3,554,557
Treasury stock	(9,900)	(9,900)
Accumulated deficit	<u>(4,543,054)</u>	<u>(3,750,045)</u>
Total stockholders' equity (deficit)	<u>624,551</u>	<u>(155,648)</u>
Total Liabilities and Stockholders' Equity	<u>\$ 699,924</u>	<u>\$ 373,245</u>

The accompanying notes are an integral part of the financial statements



**Curative Biotechnology, Inc**  
**(f/k/a Connectyx Technologies Holdings Group, Inc.)**  
**Statements of Operations**  
(Unaudited)  
Three months ended March 31,

	<u>2021</u>	<u>2020</u>
REVENUES, net	\$ -	\$ -
COST OF REVENUES	<u>-</u>	<u>-</u>
GROSS MARGIN	-	-
OPERATING EXPENSES:		
General and administrative expenses	63,912	14,532
Payroll	161,000	-
Professional fees	383,676	-
Depreciation and amortization	<u>760</u>	<u>1,325</u>
Total operating expenses	<u>609,348</u>	<u>15,857</u>
Gain of debt forgiveness	-	(379,501)
Interest expense	168,661	-
Write off of abandoned assets	<u>15,000</u>	<u>-</u>
	<u>183,661</u>	<u>(379,501)</u>
Net income (loss)	<u>\$ (793,009)</u>	<u>\$ 363,644</u>
Income (loss) per weighted average common share	<u>\$(0.0022)</u>	<u>\$0.0011</u>
Number of weighted average common shares outstanding	<u>367,186,706</u>	<u>322,800,327</u>

The accompanying notes are an integral part of the financial statements

**Curative Biotechnology, Inc**  
**(f/k/a Connectyx Technologies Holdings Group, Inc.)**  
**Statement of Stockholders' Equity (Deficit)**

(Unaudited)

Three months ended March 31,

	Number of Shares		Par Value		Treasury Stock	Additional Paid-in Capital	Accumulated Deficit	Total Stockholders' Deficit
	Common	Preferred	Common	Preferred				
<b>BALANCE, January 1, 2020</b>	322,800,327	34,402,750	\$ 32,280	\$3,440	\$ (9,900)	\$ 3,314,087	\$ (3,697,233)	\$ (357,326)
Net income	-	-	-	-	-	-	363,644	363,644
<b>BALANCE, March 31, 2020</b>	<u>322,800,327</u>	<u>34,402,750</u>	<u>\$ 32,280</u>	<u>\$3,440</u>	<u>\$ (9,900)</u>	<u>\$ 3,314,087</u>	<u>\$ (3,333,589)</u>	<u>\$ 6,318</u>

**Curative Biotechnology, Inc**  
**(f/k/a Connectyx Technologies Holdings Group, Inc.)**  
**Statement of Stockholders' Equity (Deficit)**

(Unaudited)

Three months ended March 31,

	Number of Shares		Par Value		Treasury Stock	Additional Paid-in Capital	Accumulated Deficit	Total Stockholders' Deficit
	Common	Preferred	Common	Preferred				
<b>BALANCE, January 1, 2021</b>	333,000,327	164,402,750	\$ 33,300	\$16,440	\$ (9,900)	\$ 3,554,557	\$ (3,750,045)	\$ (155,648)
Series B preferred converted to common	27,066,666	(203,000)	2,707	(20)	-	(2,686)	-	-
Series A preferred converted to common	135,836,702	(134,109,750)	13,584	(13,411)	-	(173)	-	-
Warrants issued with notes payable	-	-	-	-	-	9,533	-	9,533
Warrants issued for services	-	-	-	-	-	40,600	-	40,600
Common shares issued to settle payable	375,000	-	37	-	-	11,212	-	11,249
Common shares issued for services	6,625,000	-	662	-	-	329,913	-	330,575
Common shares issued to settle debt	10,937,499	-	1,094	-	-	655,156	-	656,250
Common shares issued for warrant exercise	10,500,000	-	1,050	-	-	523,950	-	525,000
Net income	-	-	-	-	-	-	(793,009)	(793,009)
<b>BALANCE, March 31, 2021</b>	<u>524,341,194</u>	<u>30,090,000</u>	<u>\$ 52,434</u>	<u>\$3,009</u>	<u>\$ (9,900)</u>	<u>\$ 5,122,062</u>	<u>\$ (4,543,054)</u>	<u>\$ 624,550</u>

The accompanying notes are an integral part of the financial statements

**Curative Biotechnology, Inc**  
**(f/k/a Connectyx Technologies Holdings Group, Inc.)**  
**Statements of Cash Flows**  
(Unaudited)  
Three months ended March 31,

	<u>2021</u>	<u>2020</u>
<b>CASH FLOWS FROM OPERATING ACTIVITIES:</b>		
Net (loss) income	(\$793,009)	\$363,644
Adjustments to reconcile net (loss) income to net cash used by operating activities:		
Depreciation and amortization	760	1,325
Gain on debt forgiveness	-	(379,501)
Share based compensation	371,175	-
Amortization of OID	118,613	-
Amortization of debt discount	50,048	-
Write off of abandoned assets	15,000	-
Changes in operating assets and liabilities		
Decrease in other receivable	70,000	-
Increase in accounts payable	14,852	-
(Decrease) increase in accrued expenses	<u>(70,000)</u>	<u>-</u>
Net cash provided by (used in) operating activities	<u>(222,561)</u>	<u>(14,532)</u>
<b>CASH FLOWS FROM INVESTING ACTIVITIES:</b>		
Purchase of intangible assets	<u>(8,500)</u>	<u>-</u>
Net cash (used in) investing activities	<u>(8,500)</u>	<u>-</u>
<b>CASH FLOWS FROM FINANCING ACTIVITIES:</b>		
Cash received on warrant exercise	525,000	-
Cash received from third party notes payable	<u>110,000</u>	<u>14,532</u>
Net cash (used in) provided by financing activities	<u>635,000</u>	<u>14,532</u>
Net (decrease) increase in cash	<u>403,939</u>	<u>-</u>
<b>CASH</b> , beginning of period	<u>160,607</u>	<u>-</u>
<b>CASH</b> , end of period	<u>\$ 564,546</u>	<u>\$ -</u>
<b>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:</b>		
Interest paid in cash	<u>\$ -</u>	<u>\$ -</u>
Income taxes paid in cash	<u>\$ -</u>	<u>\$ -</u>

The accompanying notes are an integral part of the financial statements

**Curative Biotechnology, Inc**  
**(f/k/a Connectyx Technologies Holdings Group, Inc.)**  
**Notes to Financial Statements**  
(Unaudited)

**NOTE 1 - NATURE OF OPERATIONS**

Curative Biotechnology Inc. (f/k/a Connectyx Technologies Holdings Group, Inc.), (CUBT) is a Florida corporation, formed as a Nevada corporation on June 29, 1995, reincorporated in Florida on October 30, 2007, with a name change November 30, 2020, which conducts business from its headquarters in Boca Raton, Florida. Curative Biotechnology, Inc. is a development stage biomedical company that seeks to develop, in-license, sub-license and bring to market products in both the Pharmaceutical and Medical Device space. The Company focuses on products that are targeted at FDA-defined "Orphan Diseases" with patient populations under 200,000 in the United States. The company leverages management's experience and business relationships with Life Science development associations as well as Life Science-focused venture capital firms to acquire Life Science candidates that fit within the company's business model. The company has established a scientific advisory board with a successful track record of bringing pharmaceuticals to market.

**NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES**

**a) Basis of Presentation** The accompanying unaudited condensed interim financial statements have been prepared in accordance with Generally Accepted Accounting Principles ("GAAP") in the United States of America ("U.S.") as promulgated by the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC"). In our opinion, the accompanying unaudited interim financial statements contain all adjustments (which are of a normal recurring nature) necessary for a fair presentation. Operating results for the three months ended March 31, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021. Certain items have been reclassified to conform with the current presentation.

**b) Use of Estimates** The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.

**(c) Cash and equivalents** For purposes of the statement of cash flows, the Company considers all highly liquid investments with maturity of three months or less when purchased to be cash equivalents.

**(d) Property and equipment** All property and equipment are recorded at cost and depreciated over their estimated useful lives, using the straight-line method. Upon sale or retirement, the cost and related accumulated depreciation are eliminated from their respective accounts, and the resulting gain or loss is included in the results of operations. Repairs and maintenance charges, which do not increase the useful lives of the assets, are charged to operations as incurred.

**(e) Intangible Assets** The useful life of intangible assets is assessed as either finite or indefinite. Following the initial recognition, intangible assets are carried at cost less any accumulated amortization and accumulated impairment losses, if any.

Intangible assets with finite useful lives are carried at cost less accumulated amortization. Amortization is calculated using the straight line method over the estimated useful lives.

Intangible assets with indefinite useful lives are not amortized, but are tested for impairment annually. The assessment of indefinite life is reviewed annually to determine whether the indefinite life continues to be supportable. If not, the change in useful life from indefinite to finite is made on a prospective basis. If impairment indicators are present, these assets are subject to an impairment review. Any loss resulting from impairment of intangible assets is expensed in the period the impairment is identified.

**Curative Biotechnology, Inc**  
**(f/k/a Connectyx Technologies Holdings Group, Inc.)**  
**Notes to Financial Statements**  
(Unaudited)

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES, continued

**(f) Impairment of Long-Lived Assets** A long-lived asset is tested for impairment whenever events or changes in circumstances indicate that its carrying value amount may not be recoverable. An impairment loss is recognized when the carrying amount of the asset exceeds the sum of the undiscounted cash flows resulting from its use and eventual disposition. The impairment loss is measured as the amount by which the carrying amount of the long-lived assets exceeds its fair value.

**(g) Financial Instruments and Fair Value Measurements** ASC 825-10 “Financial Instruments”, allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding instruments.

ASC 825 also requires disclosures of the fair value of financial instruments. The carrying value of the Company’s current financial instruments, which include cash and cash equivalents, accounts payable and accrued liabilities approximates their fair values because of the short-term maturities of these instruments.

FASB ASC 820 “Fair Value Measurement” clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. It also requires disclosure about how fair value is determined for assets and liabilities and establishes a hierarchy for which these assets and liabilities must be grouped, based on significant levels of inputs as follows:

Level 1: Quoted prices in active markets for identical assets or liabilities.

Level 2: Quoted prices in active markets for similar assets and liabilities and inputs that are observable for the asset or liability.

Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

The determination of where assets and liabilities fall within this hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

**(h) Related Party Transactions** All transactions with related parties are in the normal course of operations and are measured at the exchange amount.

**(i) Revenue Recognition** The Company adopted Accounting Standards Codification, (“ASC”), 606, “Revenue from Contracts with Customer” on January 1, 2018. This revenue recognition standard has a five step process: a) Determine whether a contract exists; b) Identify the performance obligations; c) Determine the transaction price; d) Allocate the transaction price; e) Recognize revenue when (or as) performance obligations are satisfied.

**Curative Biotechnology, Inc**  
**(f/k/a Connectyx Technologies Holdings Group, Inc.)**  
**Notes to Financial Statements**  
(Unaudited)

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES, continued

**(j) Income Taxes** Provisions for income taxes are based on taxes payable or refundable for the current year and deferred taxes on temporary differences between the amount of taxable income and pretax financial income, and between the tax bases of assets and liabilities and their reported amounts in the financial statements. Deferred tax assets and liabilities are included in the consolidated financial statements at currently enacted income tax rates applicable to the period in which the deferred tax assets and liabilities are expected to be realized or settled as prescribed in FASB ASC 740. As changes in tax laws or rates are enacted, deferred tax assets and liabilities are adjusted through the provision for income taxes.

Tax positions initially need to be recognized in the financial statements when it is more-likely-than-not the positions will be sustained upon examination by the tax authorities.

**(k) Net income (loss) per share** Basic loss per share is computed by dividing the net income (loss) by the weighted average number of common shares outstanding during the period.

**(l) Recent Accounting Pronouncements** The Company has considered recent accounting pronouncements during the preparation of these financial statements.

NOTE 3 - LIQUIDITY AND GOING CONCERN CONSIDERATIONS

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company's financial position and operating results raise substantial doubt about the Company's ability to continue as a going concern, as reflected by the net loss of \$793,009, accumulated deficit of \$4,543,054 through March 31, 2021 and \$489,174 of working capital. The ability of the Company to continue as a going concern is dependent upon commencing operations, developing sales and obtaining additional capital and financing. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. The Company is currently seeking additional capital to allow it to grow its operations

NOTE 4 - INTANGIBLE ASSETS

**(a) Website** In December 2020, the Company contracted with a third party to develop and produce a new website for the Company for a contract price of \$22,500, one-half in cash and one-half in common stock of the Company. The Company expects to amortize this cost over 3 years once it is operational. This website was placed into service in March 2021. Amortization expense for the three months ended March 31, 2021 was \$625.

**(b) Patent rights option** In October 2020, the Company entered into an option agreement to purchase certain exclusive license rights for US Patent No. 8,287,505 Ophthalmic Drop Dispensing Tip Assembly, issued October 16, 2012, from IEM, Inc., (IEM), the sole owner of this patent. The cost of this option was payment to the US Patent and Trademark Office (US PTO) of the 7.5 year PTO maintenance fee in the amount of \$1,800, which the Company paid in October 2020.

The Company has until September 30, 2021, to advise IEM in writing that it wishes to exercise this Option Right and pay IEM \$50,000 in exchange for an exclusive world-wide, royalty free perpetual license. The Company is evaluating the Patent rights, potential products and markets under this Patent.

**Curative Biotechnology, Inc**  
**(f/k/a Connectyx Technologies Holdings Group, Inc.)**  
**Notes to Financial Statements**  
(Unaudited)

NOTE 4 - INTANGIBLE ASSETS, continued

**(c) IMT504 Patent license** In October 2020, the Company entered into a license agreement with MidAtlantic BioTherapeutics, Inc., (MABT), to license the development of a pharmaceutical compound known as IMT504, as immunotherapy for late stage symptomatic rabies. The license is for worldwide use. There are certain conditions to the license, principally that the Company raise \$6.5 million to fund the development. There is not a time limit on raising these funds unless the Company utilizes a public offering process, such as Regulation A.

The total cost for this license is 20 million shares of the Company's common stock, issuable in three tranches - 1- 7 million shares upon execution of the license (which have been issued, valued at \$91,000), 2- 6.5 million shares upon the submission of an Investigational New Drug (IND) to the FDA and 3- 6.5 million shares upon the successful completion of the first rabies clinical trial of this IND. This license calls for royalties of 50% of the net profit, after reimbursement for development costs, of successfully marketed products utilizing IMT504.

A principal goal of this license is to obtain a Priority Review Voucher (PRV) issued by the US FDA, and subsequently sell the PRV to a major pharmaceutical company. The Company and MABT will split the proceeds from the sale of such PRV equally.

**(d) National Institute of Health (NIH) Patent license #1** In October 2020, the Company entered into an exclusive 24 month evaluation license of Provisional Patent Application No. 62/199,707, filed July 31, 2015; PCT Application No. PCT/US2016/044777 filed July 29, 2016 and Patent No. 10,548,987 issued February 4, 2020. This license is for the evaluation of and development of an anti-CD56 antibody drug conjugate for the treatment of glioblastoma. Should the Company develop a marketable product, the Company is then required to negotiate a new license with appropriate royalties.

This license calls for the payment of a non-creditable non-refundable license issue royalty of \$10,000, paid ½ at issuance and ½ on the one year anniversary.

**(e) National Institute of Health (NIH) Patent license #2** In January 2021 the Company entered into an NIH exclusive 36 month worldwide license of Provisional Patent Application No. 62/899,899, filed September 13, 2019 and PCT Application No. PCT/US2020/050540 filed September 11, 2020. This license is for the development of ocular metformin formulation for the treatment of retinal degenerative diseases.

This license requires two separate royalty streams of payments.

First is a royalty equal to the unreimbursed patent expenses paid by NIH, with an initial amount of \$8,500 due within 30 days of execution of the license. At the first anniversary of the license NIH will supply a statement of additional unreimbursed patent expenses paid by NIH during the year, of which the Company is required to pay 50%, with the remaining balance due on the third anniversary.

Second is an ongoing royalty schedule: an initial royalty of \$5,000 upon execution of the license, and annually thereafter as the minimum royalty amount. The license can be extended on the third anniversary to the remaining life of the licensed patent by the payment of a one-time non-refundable non-creditable royalty of \$45,000. There are three benchmark royalties - \$75,000 upon the initiation of the first Phase 2 Clinical Study; \$300,000 upon the completion of Phase 3 Clinical Study and \$600,000 upon the FDA approval of the first Licensed Product. Upon first commercial sale there is a royalty of \$100,000 each for the United States, Canada, European Union and Asian region. Last is a 3.5% of net sales royalty.

In March 2021, when the Company's new website was placed in service, the remaining unamortized cost of the Company's old website was written off as abandoned, for a total of \$15,000. Amortization expense for the three months ended March 31, 2021 and 2020, was \$625 and \$1,193, respectively.

**Curative Biotechnology, Inc**  
**(f/k/a Connectyx Technologies Holdings Group, Inc.)**  
**Notes to Financial Statements**  
(Unaudited)

**NOTE 5 - RELATED PARTY TRANSACTIONS**

From time to time the Company may enter into non-arms length transactions with related parties, however the Company exercises its best efforts to ensure that such transactions are valued on a basis comparable to a true arms length transaction.

**NOTE 6 - NOTES PAYABLE**

During the first quarter of 2021, the Company entered into 2 notes payable for a total amount of cash received of \$110,000. The notes are identical and carry a maturity of six months from inception and a 25% original issue discount (OID). The maturity is extendable at the Company's option for up to three months with a 3% per month extension fee. The notes also carry 10 warrants for each \$1 loaned.

These notes are collateralized by Preferred C shares representing 2.64% of the issued and outstanding common stock shares. Two officers holding Preferred C shares have pledged the Preferred C shares as this collateral.

During the 4<sup>th</sup> quarter of 2020 the Company entered into 13 notes payable for a total amount of cash received of \$455,000. The notes are identical and carry a maturity of six months from inception and a 25% original issue discount (OID). The maturity is extendable at the Company's option for up to three months with a 3% per month extension fee. The notes also carry 10 warrants for each \$1 loaned. These notes are collateralized by Preferred C shares representing 10.92% of the issued and outstanding common stock shares. Two officers holding Preferred C shares have pledged the Preferred C shares as this collateral.

During the first quarter of 2021, 13 of the 15 note holders converted their note receivable into shares of common stock at the rate of \$0.06 per share, for a total of 10,937,499 shares of common stock for a total of \$656,250 convertible debt.

**NOTE 7 – STOCKHOLDERS EQUITY (DEFICIT)**

At March 31, 2021 and December 31, 2020, the Company has 1,100,000,000 shares of par value \$0.0001 common stock authorized and 524,341,194 and 333,000,327 issued and outstanding, respectively. At March 31, 2021 and December 31, 2020, the Company has 200,000,000 shares of \$0.0001 par value preferred stock authorized and 0 and 134,109,750 Series A; 90,000 and 293,000 Series B and 30,000,000 and 30,000,000 Series C issued and outstanding, respectively. The preferred shares have the following respective rights and privileges:

Series A Preferred carry 10 votes for each share of common stock that each Series A shares are convertible into at the record date; is convertible into common stock aggregating 35% of the total issued and outstanding common shares at conversion date post conversion; are redeemable for the greater of 45% of the total market value of the common share or the calculation of the book value of the Company made by an independent audit firm or \$5,000,000. During the first quarter 2021, all of the Series A was converted into 135,836,702 shares of common stock.

Series B Preferred are convertible in common shares of common stock at a conversion price of \$0.0075 per share; are redeemable at a price of 125% of the purchase price paid for the shares; carry one vote for each common share that the Series B is convertible into at the record date; are senior to all other securities in the event of a liquidation. During the first quarter 2021, 203,000 shares of the Series B was converted into 27,066,666 shares of common stock.

Series C Preferred are convertible into at the record date; is convertible into common stock aggregating 30% of the total issued and outstanding common shares at conversion date post conversion; carry one vote for each common share that the Series C is convertible into at the record date.



**Curative Biotechnology, Inc**  
**(f/k/a Connectyx Technologies Holdings Group, Inc.)**  
**Notes to Financial Statements**  
(Unaudited)

NOTE 7 – STOCKHOLDERS EQUITY (DEFICIT), continued

During the first quarter 2021, the Company issued 125,000 shares of common stock in exchange for services valued at \$5,575, or \$0.0446 per share. During the first quarter 2021, the Company issued 375,000 shares of common stock to settle a payable in the amount of \$11,250. During the first quarter 2021, all of the Series A preferred stock was converted into 135,836,702 shares of common stock. During the first quarter 2021, 203,000 shares of the Series B preferred stock was converted into 27,066,666 shares of common stock. During the first quarter of 2021, 13 of the 15 note holders converted their note receivable into shares of common stock at the rate of \$0.06 per share, for a total of 10,937,499 shares of common stock for a total of \$656,250 convertible debt. During the first quarter 2021, the Company issued 10,500,000 shares of common stock upon receipt of \$525,000 in cash for the exercise of 10,500,000 warrants. During the first quarter 2021, the Company issued 6,500,000 shares of common stock for the exercise of 6,500,000 warrants in exchange for services valued at \$325,000.

During the 4<sup>th</sup> quarter 2020, the Company issued 1,700,000 shares of common stock in exchange for services valued at \$36,800, or \$0.0216 per share. During the 4<sup>th</sup> quarter 2020, the Company issued 8,500,000 shares of common stock to acquire intangible assets valued at \$106,000, or \$0.0125 per share.

NOTE 8 - WARRANTS

During the first quarter 2021, the Company issued 10,500,000 shares of common stock upon receipt of \$525,000 in cash for the exercise of 10,500,000 warrants. During the first quarter 2021, the Company issued 6,500,000 shares of common stock in exchange for services valued at \$325,000 for the exercise of 6,500,000 warrants.

In the first quarter 2021, the Company issued 1,100,000 warrants for the purchase of common stock of the Company in conjunction with the short term debt at the rate of 10 warrants for each \$1 loaned. These warrants carry an expiration of thirty six months from issuance; an exercise price of \$0.05 per share and are exercisable immediately. The warrants were recorded at a total value of \$9,533.

In the first quarter 2021, the Company issued 5,000,000 warrants for services. These warrants carry an expiration of 60 months from issuance and an exercise price of \$0.05 per share. The warrants were recorded at a total value of \$40,600.

During the 4<sup>th</sup> quarter 2020, the Company issued 4,550,000 warrants for the purchase of common stock of the Company in conjunction with the short term debt at the rate of 10 warrants for each \$1 loaned. These warrants carry an expiration of thirty six months from issuance; an exercise price of \$0.05 per share and are exercisable immediately. The warrants were recorded at a total value of \$54,555.

During the 4<sup>th</sup> quarter the Company issued 6,750,000 warrants to two people for services. These warrants carry an expiration of 60 months from issuance and an exercise price of \$0.05 per share. The warrants were recorded at a total value of \$44,135.

NOTE 9 - IMPAIRMENT OF LONG LIVED ASSETS

During the 4<sup>th</sup> quarter 2020, the Company elected to abandon the intangible assets it had been attempting to commercialize under prior management. As such the Company recorded an impairment of the remaining unamortized balance of \$32,136.

NOTE 10 - COMMITMENTS AND CONTINGENCIES

**(a) Other** The Company is subject to asserted claims and liabilities that arise in the ordinary course of business. The Company maintains insurance policies to mitigate potential losses from these actions. In the opinion of management, the amount of the ultimate liability with respect to those actions will not materially affect the Company's financial position or results of operations.

**Curative Biotechnology, Inc**  
**(f/k/a Connectyx Technologies Holdings Group, Inc.)**  
**Notes to Financial Statements**  
(Unaudited)

NOTE 11 - CONCENTRATIONS OF CREDIT RISK

**(a) Cash** The Company maintains its cash in bank deposit accounts, which may, at times, may exceed federally insured limits. The Company had \$314,546 and zero cash balance in excess of FDIC insured limits at March 31, 2021 and December 31, 2020, respectively.

NOTE 12 - COVID-19 PANDEMIC

The Company's management is unable to predict the full impact of COVID-19 on the Company.

The corona virus pandemic and subsequent State of Florida ordered shut down did not have a significant effect upon the Company's operations. The Company's access to capital was moderately curtailed , during the pandemic. The Company, as yet, does not know what the ultimate consequences of the pandemic will be upon its business model. Because of COVID-19 and the uncertainty surrounding economic conditions moving forward the Company cannot predict the full impact, although it has had only a moderate impact to date. The Company's staff was already working remotely prior to the onset of the pandemic.